Heymach J, et al. A phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC). IASLC 2018; abstract OA02.06.
Blaasspoeling met BCG-vaccin traint afweer blaaskankerpatiënten
feb 2023 | Immuuntherapie, Uro-oncologie, Vaccinatie